ESMO 2025: Bayer and BI Report Similar Efficacy Outcomes
Bayer and BI have reported similar efficacy outcomes for sevabertinib and Hernexeos in HER2-mutant NSCLC.
At the European Society of Medical Oncology (ESMO) 2025, held in Berlin, Germany, two important datasets were presented for first-line metastatic non-small cell lung cancer (NSCLC) with HER2 activating mutations.
- This subtype represents 2-4% of NSCLC patients.
- Outcomes are generally suboptimal for HER2-mutant disease.
- Patient with these driver mutations do not respond well to current immunotherapy-based standard of Merck and Co’s Keytruda (pembrolizumab) with or without chemotherapy.
Enhertu (trastuzumab deruxtecan) is currently approved after prior systemic therapy in HER2-mutant NSCLC and is commonly used in the second line.
No quote available in the text.
Author's summary: Bayer and BI report similar efficacy for sevabertinib and Hernexeos.
More News
- Minnesota Timberwolves Put on a Show in Sacramento, Dismantling Kings in a 144-117 Rout
- Rack Centre Partners with EdgeNext to Launch Content Delivery Network (CDN) and Cloud Hosting Services in Nigeria | Africa24 TV
- RAAF Hercules fleet hits 170,000 flight hour milestone
- Letters to the Editor, Sunday Nov. 9
- Instant Reaction: Canucks lose 5-4 in OT vs. Avalanche after gutsy comeback effort
- The Rising Career of Drew O'Connor in Hockey - Info Petite Nation
- The man who would be king
- Avalon flags major upgrades ahead of international relaunch
- Swedish engineering company highlights China as key market - Scandasia
- Who Was TikToker, Michael Willis Heard? Life Coach, Spiritual Mentor, Allegedly Had An Asthma Attack